Turkey: Patent use and compulsory licences

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Turkey: Patent use and compulsory licences

New IP law abolished the provisions concerning the use requirement of patents and evidence on use detailed in the Decree Law on the Protection of Patent Rights. Instead, IP law now mentions the use requirement within the provision on compulsory licences, as a consequence of non-use of a patent.

Accordingly, a patent owner must use the patented invention. When assessing the use, market conditions and conditions under the control of the patent owner, as well as outside their control, are considered. At the end of three years after publication of a patent grant in the Bulletin or at the end of four years after the patent application date, whichever expires later, any interested party can request the issue of a compulsory licence. They can make this request on the grounds that at the date of demand for a compulsory licence the patented invention is not being used, no serious and real measures have been taken to make use of the patented invention or the level of current use does not satisfy domestic demand. The same applies to an uninterrupted cease of use of a patent for more than three years without justified reason.

The only provision in Turkish law that provides rules about the results of not filing evidence on use of a patent is in the Regulation on the Implementation of IP Law, which states that:

"the declaration relaying whether the patent is used or not used is submitted to the Institute within a certain period and then published in the Bulletin. The patents for which no notification of use have been given within this period shall be published in the Bulletin."

The mentioned publication is a kind of announcement to third parties that the patent is not used (without a justified reason) and therefore a licence over the patent may be requested from the patent owner.

This publication can give rise to a compulsory licence demand. In the case of a compulsory licence demand, a fixed legal procedure must be followed, and the evidence filed before the Turkish Patent Office (TPO) before this procedure starts can only be an indication of use of the patent. The evidence of use filed before the TPO does not automatically prevent the third party from demanding a compulsory licence. However, the patent holder may refer to this document/evidence while claiming that it does use the patent or there is a legitimate reason for non-use of the patent.

The lack of such a document or evidence does not ease, quicken or remove the fixed legal procedure to be followed by the third party demanding the compulsory licence. The third party has to apply to the court for a compulsory licence and must prove that it has tried hard to obtain from the patent owner a contractual licence on reasonable commercial terms and within a reasonable period of time.

These IP law provisions show that filing evidence on use of a patent or filing a statement before the TPO explaining the legitimate reason for not using the patent is optional. However, we believe that such a filing may have a role in discouraging a third party from demanding a compulsory licence by alleging non-use of the patent without a legitimate reason.

Selin Sinem Erciyas

Gün + Partners

Kore Şehitleri Cad. 17

Zincirlikuyu 34394

İstanbul, Turkey

Tel: + (90) (212) 354 00 00

Fax: + (90) (212) 274 20 95

gun@gun.av.tr

gun.av.tr

more from across site and SHARED ros bottom lb

More from across our site

Regulatory changes and damages risks are prompting Canadian firms and clients to opt for settlements in generic and biosimilar cases
News of Via Licensing Alliance adding two new members and Nokia’s proposal to extend interim licences to Warner Bros Discovery and Paramount were also among the top talking points
A new claim filed by Ericsson, and a request for access to documents, were also among recent developments
Cooley and Stikeman Elliott advised 35Pharma on the deal, which will allow GSK to get its hands on S235, an investigational medicine for pulmonary hypertension
Simon Wright explains why the UK should embrace the possibility of rejoining the UPC, and reveals how CIPA is reacting to this month’s historic Emotional Perception AI case at the UK Supreme Court
Matthew Grady of Wolf Greenfield says AI presents an opportunity in patent practice for stronger collaboration between in-house and outside counsel
Aparna Watal, head of trademarks at Halfords IP, discusses why lawyers must take a stand when advising clients and how she balances work, motherhood and mentoring
Discussion hosted by Bird & Bird partners also hears that UK courts’ desire to determine FRAND rates could see the jurisdiction penalised in a similar way to China
The platform’s proactive intellectual property enforcement helps brands spot and kill fakes, so they can focus on growth. Managing IP learns more about the programme
Hire of José María del Valle Escalante to lead the firm’s operations in ‘dynamic’ Catalonia and Aragon regions follows last month’s appointment of a new chief information officer
Gift this article